Product Description
Canagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Canagliflozin is also used to reduce the risk of stroke, heart attack, or death in people who have type 2 diabetes along with heart and blood vessel disease. Canagliflozin is also used to reduce the risk of end-stage kidney disease, worsening of kidney function, needing to be hospitalized for heart failure, and cardiovascular death in people who have type 2 diabetes along with severe kidney disease. Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. Canagliflozin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood). (Sourced from: https://medlineplus.gov/druginfo/meds/a613033.html)
Mechanisms of Action: SGLT2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: Heart Failure | Acidosis | Diabetic Ketoacidosis | Diabetic Nephropathy | General Diabetes | Type 2 Diabetes | Albuminuria | Kidney Diseases | Heart Failure | Acidosis | Diabetic Ketoacidosis | Diabetic Nephropathy | General Diabetes | Type 2 Diabetes | Albuminuria | Kidney Diseases
Known Adverse Events: Urinary Tract Infections | Asthenia | Diarrhea | Flatulence
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, China, Greece, India, Israel, Malaysia, Mexico, Philippines, Poland, Russia, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CR108298 | P3 |
Completed |
Type 2 Diabetes |
2023-09-20 |
|
| CTR20181597 | P3 |
Completed |
Type 2 Diabetes |
2023-09-20 |